Mersana Therapeutics Financials
| MRSN Stock | USD 0.52 0.02 4.00% |
Mersana |
Mersana Therapeutics Stock Summary
Mersana Therapeutics competes with Terns Pharmaceuticals, Amylyx Pharmaceuticals, Acumen Pharmaceuticals, Inozyme Pharma, and X4 Pharmaceuticals. Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates for cancer patients with unmet need. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Mersana Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 169 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US59045L1061 |
| CUSIP | 59045L106 |
| Location | Massachusetts; U.S.A |
| Business Address | 840 Memorial Drive, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.mersana.com |
| Phone | 617 498 0020 |
| Currency | USD - US Dollar |
Mersana Therapeutics Key Financial Ratios
Mersana Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mersana Therapeutics's current stock value. Our valuation model uses many indicators to compare Mersana Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mersana Therapeutics competition to find correlations between indicators driving Mersana Therapeutics's intrinsic value. More Info.Mersana Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mersana Therapeutics' earnings, one of the primary drivers of an investment's value.Mersana Therapeutics Systematic Risk
Mersana Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mersana Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Mersana Therapeutics correlated with the market. If Beta is less than 0 Mersana Therapeutics generally moves in the opposite direction as compared to the market. If Mersana Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mersana Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mersana Therapeutics is generally in the same direction as the market. If Beta > 1 Mersana Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Mersana Therapeutics Thematic Clasifications
Mersana Therapeutics is part of several thematic ideas from Cancer Fighters to Pharmaceutical Products. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasMersana Therapeutics March 1, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Mersana Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mersana Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mersana Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Mersana Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mersana Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 53.67 | |||
| Value At Risk | (13.89) | |||
| Potential Upside | 9.05 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.